Digestive Diseases and Sciences

, Volume 50, Supplement 1, pp S3–S11 | Cite as

15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications

  • Tetsuo Arakawa
  • Kazuhide Higuchi
  • Yasuhiro Fujiwara
  • Toshio Watanabe
  • Kazunari Tominaga
  • Eiji Sasaki
  • Nobuhide Oshitani
  • Toshikazu Yoshikawa
  • Andrzej S. Tarnawski


Rebamipide, a gastroprotective drug, was developed in Japan for the treatment of peptic ulcer disease. It was proven superior to the former same category drug cetraxate in a randomized, controlled, double-blind, comparative clinical study in 1989. Rebamipide's mechanisms of actions are different from anti-secretory drugs; it accelerates and improves the quality of ulcer healing and reduces ulcer recurrence rate. Numerous studies have been conducted to explain the mechanisms responsible for these actions, 37 papers were published by 1998. Major properties of rebamipide include: stimulation of prostaglandin and mucus glycoprotein synthesis, inhibition of reactive oxygen species, inflammatory cytokines and chemokines, and inhibition of neutrophils activation. Since 1998, 107 papers were published, clarifying further effects of rebamipide on cyclooxygenase-2, prostaglandin E receptors, growth factors (i.e., HGF, EGF, and VEGF), heat-shock proteins, nitric oxide, adhesion molecules, neutrophils, and Helicobacter pylori- and NSAID-related pathology. Moreover, inhibitory action of rebamipide on gastric cancer growth has also been shown. In this issue we reviewed recent advances in understanding of rebamipide's mechanism of action and its newest clinical applications.

Key Words

growth factor cytokine peptic ulcer prostaglandin cancer H. pylori NSAIDs 


  1. 1.
    Takemoto T, Namiki M, Yachi A, Masamune O, Ishikawa M, Goto Y, Kimura K, Itoh S, Matsuo Y, Kobayashi M, Oka H, Tsuchiya M, Kurokawa K, Yokoyama I, Okabe H, Miwa T, Kohli Y, Nakazawa S, Takeuchi T, Uchino H, Miyake T, Kawai K, Kamada T, Kobayashi K, Ohshiba S, Tsuji T, Kajiyama G, Shimada Y, Okazaki Y, Kishi S, Nawata H, Tanikawa K, Hayakawa H, Hashimoto S: Effect of rebamipide (OPC-12759) on gastric ulcer healing multicenter, double-blind, cetraxate controlled clinical study. Rinsho Seijin-byo 19:1265–1291, 1989Google Scholar
  2. 2.
    Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A: Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43(Suppl):5S–13S, 1998PubMedGoogle Scholar
  3. 3.
    Kleine A, Kluge S, Peskar BM: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci 38:1441–1449, 1993CrossRefPubMedGoogle Scholar
  4. 4.
    Yoshikawa T, Naito Y, Tanigawa T, Kondo M: Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung 43:363–366, 1993PubMedGoogle Scholar
  5. 5.
    Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M: Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18:117–123, 1995CrossRefPubMedGoogle Scholar
  6. 6.
    Yoshikawa T, Arakawa T: Bioregulation and its Disorders in the Gastrointestinal Tract. Tokyo, Blackwell Science, 1998Google Scholar
  7. 7.
    Nebiki H, Arakawa T, Higuchi K, Kobayashi K: Quality of ulcer healing influences the relapse of gastric ulcers in humans. J Gastroenterol Hepatol 12:109–114, 1997PubMedGoogle Scholar
  8. 8.
    Arakawa T, Nebiki H, Uchida T, Kimura S, Higuchi K, Kobayashi K: Clinical assessment of quality of ulcer healing—a new concept to rank healed peptic ulcer. Eur J Gastroenterol Hepatol 5(Suppl 3):S87–S92, 1993Google Scholar
  9. 9.
    Higuchi K, Arakawa T, Nebiki H, Uchida T, Fujiwara Y, Ando K, Yamasaki K, Takaishi O, Fukuda T, Kobayashi K, Kuroki T: Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci 43(Suppl):S99–S106, 1998Google Scholar
  10. 10.
    Arakawa T, Watanabe T, Fukuda T, Higuchi K, Takaishi O, Yamasaki K, Kobayashi K, Tarnawski A: Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increase future ulcer recurrence. Dig Dis Sci 41:2055–2061, 1996CrossRefPubMedGoogle Scholar
  11. 11.
    Watanabe T, Arakawa T, Fukuda T, Higuchi K, Kobayashi K: Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta. Am J Pathol 150:971–979, 1997PubMedGoogle Scholar
  12. 12.
    Watanabe T, Higuchi K, Tominaga K, Fujiwara Y, Arakawa T: Acid regulates inflammatory response in a rat model of induction of gastric ulcer recurrence by interleukin 1beta. Gut 48:774–781, 2001CrossRefPubMedGoogle Scholar
  13. 13.
    Watanabe T, Higuchi K, Hamaguchi M, Shiba M, Tominaga K, Fujiwara Y, Matsumoto T, and Arakawa T: Monocyte chemotactic protein-1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-α. Am J Physiol Gastrointest Liver Physiol 287:G919–G928, 2004CrossRefPubMedGoogle Scholar
  14. 14.
    Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112:1442–1447, 1997PubMedGoogle Scholar
  15. 15.
    Befrits R, Sjostedt S, Odman B, Sorngard H, Lindberg G: Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 5:202–205, 2000CrossRefPubMedGoogle Scholar
  16. 16.
    Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT: Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 121:1120–1126, 2001CrossRefPubMedGoogle Scholar
  17. 17.
    Azuma T, Suto H, Ito Y, Ohtani M, Dojo M, Kuriyama M, Kato T: Gastric leptin and Helicobacter pylori infection. Gut 49:324–329, 2001CrossRefPubMedGoogle Scholar
  18. 18.
    Fujiwara Y, Higuchi K, Arafa UA, Uchida T, Tominaga K, Watanabe T, Arakawa T: Long-term effect of Helicobacter pylori eradication on quality of life, body mass index, and newly developed diseases in Japanese patients with peptic ulcer disease. Hepatogastroenterology 49:1298–1302, 2002PubMedGoogle Scholar
  19. 19.
    Takaishi O, Arakawa T, Fujiwara Y, Fukuda T, Otani K, Yamasaki K, Higuchi K, Kuroki T: Inhibition by 16,16-dimethyl prostaglandin E2 of tumor necrosis factor-alpha and interleukin-1beta production and messenger RNA expression in human monocytes stimulated by Helicobacter pylori. Dig Dis Sci 44:2405–2411, 1999CrossRefPubMedGoogle Scholar
  20. 20.
    Haruma K, Ito M: Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Aliment Pharmacol Ther 18(Suppl 1):153–159, 2003CrossRefPubMedGoogle Scholar
  21. 21.
    Aihara M, Azuma A, Takizawa H, Tsuchimoto D, Funakoshi Y, Shindo Y, Ohmoto Y, Imagawa K, Kikuchi M, Mukaida N, Matsushima K: Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci 43(Suppl):174S–180S, 1998PubMedGoogle Scholar
  22. 22.
    Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, Fujii T, Yoshida N, Kondo M, Sasaki E: Rebamipide protects against Indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci 43(Suppl):83S–89S, 1998PubMedGoogle Scholar
  23. 23.
    Sun WH, Tsuji S, Tsujii M, Gunawan ES, Kawai N, Kimura A, Kakiuchi Y, Yasumaru M, Iijima H, Okuda Y, Sasaki Y, Hori M, Kawano S: Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther 295:447–452, 2000PubMedGoogle Scholar
  24. 24.
    Suetsugu H, Ishihara S, Moriyama N, Kazumori H, Adachi K, Fukuda R, Watanabe M, Kinoshita Y: Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med 136:50–57, 2000CrossRefPubMedGoogle Scholar
  25. 25.
    Tarnawski A, Arakawa T, Kobayashi K: Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 43(Suppl):90S–98S, 1998CrossRefPubMedGoogle Scholar
  26. 26.
    Udagawa A, Shiota G, Ichiba M, Murawaki Y: Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol 38:141–146, 2003PubMedGoogle Scholar
  27. 27.
    Watanabe T, Higuchi K, Hamaguchi M, Tanigawa T, Wada R, Tominaga K, Fujiwara Y, Arakawa T: Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by Helicobacter pylori infection in Mongolian gerbils. Dig Dis Sci 47:1582–1589, 2002CrossRefPubMedGoogle Scholar
  28. 28.
    Tarnawski AS, Chai J, Pai R, Chiou SK: Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci 49:202–209, 2004CrossRefPubMedGoogle Scholar
  29. 29.
    Tsukimi Y, Fujishita T, Nakajima K, Okabe S: Effect of rebamipide on cell death induced by combined treatment of mild heat shock and quercetin in RGM-1 cells: a role for HSP70 induction. Pharmacology 64:28–35, 2002CrossRefPubMedGoogle Scholar
  30. 30.
    Takaishi O, Arakawa T, Yamasaki K, Fujiwara Y, Uchida T, Tominaga K, Watanabe T, Higuchi K, Fukuda T, Kobayashi K, Kuroki T: Protective effect of rebamipide against ammonia-induced gastric mucosal lesions. Dig Dis Sci 43 (Suppl):78S–82S, 1998PubMedGoogle Scholar
  31. 31.
    Kim H, Seo JY, Kim KH: Inhibition of lipid peroxidation, NF-kappaB activation and IL-8 production by rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci 45:621–628, 2000CrossRefPubMedGoogle Scholar
  32. 32.
    Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL: Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 95:1838–1839, 2000CrossRefPubMedGoogle Scholar
  33. 33.
    Farhadi A, Keshavarzian A, Fitzpatrick LR, Mutlu E, Zhang Y, Banan A: Modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on neutrophil reactive oxygen species production in presence of a novel antioxidant, rebamipide. Dig Dis Sci 47:1342–1348, 2002CrossRefPubMedGoogle Scholar
  34. 34.
    Hayashi S, Sugiyama T, Amano K, Isogai H, Isogai E, Aihara M, Kikuchi M, Asaka M, Yokota K, Oguma K, Fujii N, Hirai Y: Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother 42:1895–1899, 1998PubMedGoogle Scholar
  35. 35.
    Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M: Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 41:1139–1144, 1996CrossRefPubMedGoogle Scholar
  36. 36.
    Matysiak-Budnik T, de Mascarel A, Abely M, Mayo K, Heyman M, Megraud F: Positive effect of rebamipide on gastric permeability in mice after eradication of Helicobacter felis. Scand J Gastroenterol 35:470–475, 2000CrossRefPubMedGoogle Scholar
  37. 37.
    Hong WS, Jung HY, Yang SK, Myung SJ, Kim JH, Min YI, Chung MH, Lee HS, Kim HW: The antioxidant effect of rebamipide on oxygen free radical production by H. pylori-activated human neutrophils: in comparison with N-acetylcysteine, ascorbic acid and glutathione. Pharmacol Res 44:293–297, 2001CrossRefPubMedGoogle Scholar
  38. 38.
    Haruma K, Ito M, Kido S, Manabe N, Kitadai Y, Sumii M, Tanaka S, Yoshihara M, Chayama K: Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci 47:862–867, 2002CrossRefPubMedGoogle Scholar
  39. 39.
    Murakami K, Okajima K, Harada N, Isobe H, Okabe H: Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. Dig Dis Sci 43(Suppl):139S–142S, 1998PubMedGoogle Scholar
  40. 40.
    Yamasaki K, Arakawa T, Takaishi O, Higuchi K, Kobayashi K, Kuroki T: Influence of rebamipide on indometacin-induced gastric hemorrhage in rats under restraint stress. Arzneimittelforschung 49:359–365, 1999PubMedGoogle Scholar
  41. 41.
    Kim CD, Kim YK, Lee SH, Hong KW: Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappaB-dependent pathway. J Pharmacol Exp Ther 294:864–869, 2000PubMedGoogle Scholar
  42. 42.
    Kobayashi T, Zinchuk VS, Garcia del Saz E, Jiang F, Yamasaki Y, Kataoka S, Okada T, Tsunawaki S, Seguchi H: Suppressive effect of rebamipide: an antiulcer agent, against activation of human neutrophils exposed to formyl-methionyl-leucyl-phenylalanine. Histol Histopathol 15:1067–1076, 2000PubMedGoogle Scholar
  43. 43.
    Nagano C, Azuma A, Ishiyama H, Sekiguchi K, Imagawa K, Kikuchi M: Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther 297:388–394, 2001PubMedGoogle Scholar
  44. 44.
    Higuchi K, Tanigawa T, Hamaguchi M, Takashima T, Sasaki E, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Matsumoto T, Watanabe T, Arakawa T: Comparison of the effects of rebamipide with those of cimetidine on chronic gastritis associated with Helicobacter pylori in Mongolian gerbils. Aliment Pharmacol Ther. 18(Suppl 1):1–7, 2003CrossRefGoogle Scholar
  45. 45.
    Hahm KB, Kim DH, Lee KM, Lee JS, Surh YJ, Kim YB, Yoo BM, Kim JH, Joo HJ, Cho YK, Nam KT, Cho SW: Effect of long-term administration of rebamipide on Helicobacter pylori infection in mice. Aliment Pharmacol Ther 18(Suppl 1):24–38, 2003CrossRefPubMedGoogle Scholar
  46. 46.
    Tarnawski A, Pai R, Chiou SK, Chai J, Chu EC: Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun 334:207–212, 2005CrossRefPubMedGoogle Scholar
  47. 47.
    Wong BC, Chang FY, Abid S, Abbas Z, Lin BR, Van Rensburg C, Chen PC, Schneider H, Simjee AE, Hamid SS, Seebaran A, Zhang J, Destefano M, Lam SK: Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 14:1529–1535, 2000CrossRefGoogle Scholar
  48. 48.
    Lai KC, Hui WM, Wong BC, Hu WH, Lam SK: Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther 14:1071–1076, 2000CrossRefPubMedGoogle Scholar
  49. 49.
    Higuchi K, Fujiwara Y, Tominaga K, Watanabe T, Shiba M, Nakamura S, Oshitani N, Matsumoto T, Arakawa T: Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 17:111–117, 2003CrossRefGoogle Scholar
  50. 50.
    Terano A et al.: A new combination therapy for gastric ulcer: a preliminary study of Helicobacter pylori eradication triple therapy followed by gastroprotective treatment with rebamipide. J Gastroenterol Hepatol, in pressGoogle Scholar
  51. 51.
    Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y: Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs Res Dev 4:19–28, 2003Google Scholar
  52. 52.
    Ro JY, Kim JY, Kim KH: The inhibitory mechanism of rebamipide on the mediator release in the guinea pig lung mast cells activated with specific antigen–antibody reactions. Pharmacology 63:175–184, 2001CrossRefPubMedGoogle Scholar
  53. 53.
    Saad SY, Najjar TA, Al-Sohaibani MO: The effect of rebamipide on cisplatin-induced nephrotoxicity in rats. Pharmacol Res 42:81–86, 2000CrossRefPubMedGoogle Scholar
  54. 54.
    Hong KW, Kim KE, Rhim BY, Lee WS, Kim CD: Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci 43(Suppl):154S–159S, 1998PubMedGoogle Scholar
  55. 55.
    Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y: Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 45:1608–1616, 2000CrossRefPubMedGoogle Scholar
  56. 56.
    Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S: Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea 23:613–619, 2004PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Tetsuo Arakawa
    • 1
  • Kazuhide Higuchi
    • 1
  • Yasuhiro Fujiwara
    • 1
  • Toshio Watanabe
    • 1
  • Kazunari Tominaga
    • 1
  • Eiji Sasaki
    • 1
  • Nobuhide Oshitani
    • 1
  • Toshikazu Yoshikawa
    • 2
  • Andrzej S. Tarnawski
    • 3
  1. 1.Department of GastroenterologyOsaka City University Graduate School of MedicineOsakaJapan
  2. 2.Department of Inflammation and Immunology, Graduate School of Medical ScienceKyoto Prefectural University of MedicineKyotoJapan
  3. 3.Department of Medicine, VA Long Beach Healthcare SystemLong Beach and the University of CaliforniaIrvineUSA

Personalised recommendations